Thursday 16 October, 2025
Objectives: The aims of our work were: i) to describe the reverse transcriptase inhibitor stavudine pharmacokinetics (PK) in populations of…
Read moreposter
Nonparametric Population Analysis Of Amikacin Pharmacokinetic Data In A Pediatric Population.
Thursday 16 October, 2025
The aims of our work were: i) to describe amikacin pharmacokinetics in populations of neonates, infants and children; ii) to…
Read moreInformation indexes for exploratory data analysis in population pharmacokinetics
Thursday 16 October, 2025
Indexes derived from information theory were used to select the most appropriate model for the statistical distribution, to detect atypical…
Read moreThe Efficiency of Mixed Effect Modelling to Detect Metabolism-Based Drug-Drug Interactions (mDDI)
Thursday 16 October, 2025
PDF of poster Purpose. To assess, by simulation, factors that influence the detection of mDDIs in phase 2/3 clinical trials…
Read moreImproved Computational Methods for Statistically Consistent and Efficient PK/PD Population Analysis
Thursday 16 October, 2025
Objectives: Most current PK/PD population analysis methodologies are based on parametric maximum likelihood estimators that use approximations such as FO,…
Read moreD-Optimal Design for Multivariate Response: Prospective Planning of a Beta-blocker Study in Rat Involving Cassette Dosing
Thursday 16 October, 2025
Objective: To suggest optimal sampling times for an iv bolus experiment to study the tissue disposition kinetics of eight beta-blockers…
Read morePopulation Optimal Design for Multivariate Response Pharmacokinetic Models
Thursday 16 October, 2025
Objective: To develop a methodology for individual and population multivariate response design for pharmacokinetic models. To suggest optimal sampling times for…
Read moreRobust fitting of pharmacokinetic models to Phase II/III clinical trial data
Thursday 16 October, 2025
PDF of poster Pharmacokinetic analysis of Phase II/III trial data is often hampered by uncertainties in the data. This is…
Read morePopulation pharmacokinetics of a new anticoagulant drug in clinical development
Thursday 16 October, 2025
PDF of poster Objectives & Background: A population pharmacokinetic model for an intravenous anticoagulant drug in clinical development that acts…
Read morePK/PD-Modeling (PK/PD) and Clinical Trial Simulation (CTS) of Early Clinical Data of a New Oral Direct Thrombin Inhibitor (Dabigatran Etexilate)
Thursday 16 October, 2025
PDF of poster Objectives: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism…
Read more